Overview

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Status:
Terminated
Trial end date:
2015-11-02
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation